Boostimmune

Developer of therapeutics for cancer treatment

placeSeoul, Seoul, South Korea calendar_todayFounded 2021 groups5 employees language boostimmune.com

Innovation

3 patent families (1 granted) — focus: Chemistry & metallurgy, Physics & computing, Human necessities; filing pace active. Cited 25 times.

YearFilings
20242
20252
20261

Investor mix

8 investors on record; lead investors include Mirae Asset, Aju, Company K Partners, Smile Gate Investment.

Investor typeCountShare
Venture capital225%
Private equity225%
Bank & private debt113%
Other / undisclosed338%
Coming soon